Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 255

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 255
---
 is eligible to receive from us (a) up to an aggregate of $265 million upon the achievement of certain development milestones, and (b) up to an aggregate of $540 million upon the achievement of certain commercial milestones, in each case, across all ACD Programs. WuXi Biologics is also entitled to running royalties during the agreed upon royalty term ranging from low-single-digit toupper-single-digit percentages of annual net sales of licensed products in the territory.

| • |     | PIPE Financing. On December 19, 2024, Aadi entered into the Subscription Agreement with PIPE                                                                                                                                                                                                                                                                                 
 Investors, pursuant to which Aadi agreed to sell to the PIPE Investors (i) 21,592,000 shares of Aadi’s common stock, par value $0.0001 per share, at a purchase price of $2.40 per share, and (ii) 20,076,500 Pre-Funded Warrants, at a purchase price of $2.3999 per Pre-Funded Warrant, for aggregate gross proceeds of $100 million. The closing of the PIPE Financing is 
 expected to occur on a date that is no later than five business days from the date on which stockholder approval is obtained.                                                                                                                                                                                                                                                |

- 180 -

| enrollment, but continue dosing previously enrolled patients, in two, ongoing Phase 2 trials of FYARRO for advanced or recurrent endometrioid-type endometrial cancer (EEC) and neuroendocrine         
 tumors (NETs). Both studies have enrolled sufficient patients (n=24 and n=12 for EEC and NETs, respectively) to assess initial efficacy signals, with results expected to be reported at a later date. |

| • |     | New Member of the Board. On December 19, 2024, our board of directors appointed Baiteng Zhao,                                                                                                                                                    
 Ph.D. as a new member of the board. Dr. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024. Prior to   
 ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug 
 candidates.                                                                                                                                                                                                                                      |

BMS License Agreement We have exclusive rights for certain patents and a non